Cerevel Therapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Cerevel Therapeutics sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).

21 total trials none currently recruiting 20 completed early-phase tilt top decile by trial count

Cerevel Therapeutics: 21 sponsored US clinical trials, none currently recruiting.

Cerevel Therapeutics sponsors 21 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 20 completed. 0 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Participants, with 2 trials.

Top-decile sponsor footprint

Cerevel Therapeutics ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 78/100

20 of 21 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

21 total, page 1 of 1

COMPLETED Phase 1

A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants

NCT06435923
COMPLETED Phase 1

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

NCT06366243
COMPLETED Phase 1

A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants

NCT06301971
COMPLETED Phase 1

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

NCT05965219
COMPLETED Phase 1

A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants

NCT05933187
COMPLETED Phase 1

The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants

NCT05915546
COMPLETED Phase 1

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

NCT05824143
COMPLETED Phase 1

Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing

NCT05547542
COMPLETED Phase 1

Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease

NCT05610189
COMPLETED Phase 1

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

NCT05581823
COMPLETED Phase 1

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

NCT05404542
COMPLETED Phase 1

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

NCT05404529
COMPLETED Phase 1

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

NCT05245539
COMPLETED Phase 1

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

NCT05106309
COMPLETED Phase 1

Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants

NCT05123079
COMPLETED Phase 1

A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants

NCT05138653
COMPLETED Phase 1

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

NCT04787302
COMPLETED Phase 1

An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects

NCT04241393
COMPLETED Phase 1

A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease

NCT04295642
TERMINATED Phase 1

A Single Ascending Dose Trial of CVL-936 in Healthy Subjects

NCT04232878
COMPLETED Phase 1

A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia

NCT04136873

Phase Distribution

PhaseTrial count
Phase 1 21

Therapeutic Areas

Healthy Participants 2
Parkinson Disease 1
Blood Pressure 1
Healthy Volunteers 1
Schizophrenia 1
Healthy 1

How the Cerevel Therapeutics early-phase archive is shaped

21 indexed studies, none listed as recruiting (0% open); 20 completed (95%).

Phase mix: 0 late (III/IV) vs 21 early (I/II) (early-phase heavy).

Top condition: Healthy Participants (2 trials), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Cerevel Therapeutics: archived-pipeline peers nationwide

Peers matched on 21 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Cerevel Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0510152025 0%2%4%6%8%10% Total trials Recruiting share Cerevel TherapeuticsAEterna ZentarisAmphastar PharmaceuticalsApellis PharmaceuticalsArray Biopharma, now a wholly owned subsidiary of Pfizer10xBio22nd Century Group23andMe3-C Institute for Social Development
Cerevel Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Cerevel Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 21 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Cerevel Therapeutics page

21 registered trials is a research-attention snapshot, not an endorsement of Cerevel Therapeutics or any single study.

  • None of Cerevel Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy Participants is the condition Cerevel Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Participants trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Cerevel Therapeutics pipeline card: 21 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.